Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752774 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
A Phase 1 study of Spasticity, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT04752774: Recruiting Phase 1 study of Spasticity, sponsored by Ipsen.
NCT04752774 is a Phase 1 study of Spasticity that is actively recruiting participants, run by Ipsen. The registered enrollment target is 240 participants, above the 62-participant average among 8 other Spasticity trials with a reported enrollment target (287% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04752774, a Phase 1 study of Spasticity, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Primary Outcome
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL IPN10200
- BIOLOGICAL Dysport
Study Locations (20)
Other
- Medical University Innsbruck, Department of Neurology - Innsbruck
- Kepler University Hospital GmbH, Department of Neurology and Psychiatry - Linz
- Brothers of Charity Hospital Linz, Department of Neurology I - Linz
- Medical University Vienna, Department of Neurology - Vienna
- Multiprofile Hospital for Active Treatment "Heart and Brain" - Pleven
- Medical Center "Rusemed" EOOD - Rousse
- Multiprofile Hospital for Active Treatment of Neurology and Psychiatry "Sveti Naum", Sofia, Neurological Diseases Clinic for Neurodegenerative and Peripheral Neurological Diseases - Sofia
- Diagnostic Consulting Center - Convex EOOD - Sofia
- Medical Center Medica Plus Ltd - Veliko Tarnovo
- University Hospital Hradec Kralove, Clinic of Neurology - Hradec Králové
- Hospital Jihlava, Department of Neurology - Jihlava
- University Hospital Ostrava, Clinic of Neurology, Center for Demyelinating diseases - Ostrava
- Regional Hospital Pardubice, Clinic of Neurology - Pardubice
- University Hospital Kralovske Vinohrady, Clinic of Neurology - Prague
- General University Hospital in Prague, Clinic of Neurology - Prague
California
- Rancho Los Amigos National Rehab - Downey
Kansas
- Kansas Institute of Research - Overland Park
Michigan
- Quest Research Institute - Farmington Hills
Pennsylvania
- Einstein Physical Medicine and Rehabilitation at Elkins Park - Elkins Park
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
What NCT04752774 shows while recruiting
NCT04752774 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 62-participant average among 8 other Spasticity trials with a reported enrollment target (287% higher).
The record links to 1 condition, with Spasticity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04752774 names 20 study sites across 6 states, led by Other, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT04752774 about?
NCT04752774 is a clinical study titled "A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.". The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper lim...
What is the current status of trial NCT04752774?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2021-04-29. Estimated completion is 2027-10-30.
What conditions does trial NCT04752774 study?
This clinical trial studies the following conditions: Spasticity.
What interventions are being tested in trial NCT04752774?
The interventions under investigation include: Placebo (DRUG), IPN10200 (BIOLOGICAL), Dysport (BIOLOGICAL).
Who is sponsoring clinical trial NCT04752774?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752774 being conducted?
This trial has 20 study locations across California, Kansas, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spasticity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04752774's enrollment target sits among peer trials
240 2nd of 8 the highest of 8 other Spasticity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spasticity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dry Needling in Multiple Sclerosis
RECRUITING · NA
-
Leg Stretching Using an Exoskeleton on Demand for People With Spasticity
RECRUITING · NA
-
Spinal Cord Stimulation to Augment Activity Based Therapy
COMPLETED · NA
-
Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
COMPLETED · NA
-
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
COMPLETED · Phase 4
-
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI